Combination immunotherapy shrank melanoma that has spread to the brain in more than half of the patients in a clinical trial reported in the New England Journal of Medicine led by an investigator at The University of Texas MD Anderson Cancer Center.
The University of Texas MD Anderson Cancer Center and Berkeley Lights, Inc. today announced the launch of Optera Therapeutics Corp, a biopharmaceutical company developing cell therapies with scalable manufacturing solutions for cancer.
A powerful resistance mutation that appeared to emerge in melanoma after a patient received a targeted therapy combination, instead was lurking in the tumor all along, primed to thwart treatment before it began, researchers at The University of Texas MD Anderson Cancer Center report online at Cancer Discovery.
Obese patients with metastatic melanoma who are treated with targeted or immune therapies live significantly longer than those with a normal body mass index (BMI), investigators report in a study published in Lancet Oncology of 1,918 patients in six independent clinical cohorts.
This effect, referred to as the “Obesity Paradox”, principally manifested itself in men, said Jennifer McQuade, M.D., lead author and instructor of Melanoma Medical Oncology at The University of Texas MD Anderson Cancer …
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Patients who had no sign of disease at surgery after combination treatment did not progress to metastasis.
In recognition of their contributions to basic, translational, and clinical research, six faculty members from The University of Texas MD Anderson Cancer Center have been named Fellows of the American Association for the Advancement of Science (AAAS).
V. Craig Jordan, Ph.D., professor of Breast Medical Oncology, has been elected to the National Academy of Medicine for his discovery of selective estrogen receptor modulators (SERMs), a class of drugs with far-reaching impact on women’s health.
Participating in twice-weekly practice of Tibetan yoga may reduce sleep disturbances and improve sleep quality in breast cancer patients receiving chemotherapy, according to a study from researchers at The University of Texas MD Anderson Cancer Center.